SCHEDULE: Paradigm BioCapital Exits Y-mAbs Therapeutics Stake

Paradigm BioCapital Advisors and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc. common stock.

Summary

• This is an Amendment No. 2 to a Schedule 13G filing by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.
• As of September 30, 2025, the reporting persons beneficially own 0 shares of Y-mAbs Therapeutics, Inc. common stock.
• This represents 0.0% of the class of securities, indicating a complete divestment of their previous holdings.
• The reporting persons disclaim beneficial ownership of any common stock other than what they directly own.
• The filing was made to report the cessation of their beneficial ownership in Y-mAbs Therapeutics.

Sentiment

Score: 5

Explanation: The filing is a factual report of a complete divestment of shares by an institutional investor group. It does not contain operational or financial news for the issuer, Y-mAbs Therapeutics, Inc. The exit of an investor can be interpreted in various ways, but the filing itself is purely factual regarding ownership change, thus maintaining a neutral sentiment.

Risks

• Potential negative market perception due to an institutional investor's complete divestment, which could lead to short-term share price volatility for Y-mAbs Therapeutics, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this ownership disclosure filing.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor were they acquired or held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine ownership disclosure within the biotechnology sector. The complete divestment by an institutional investor group, while not uncommon, can sometimes prompt market speculation regarding the investor's view on the company's future prospects or a shift in their investment strategy. However, the filing itself provides no specific reasons for the divestment.

Stakeholder Impact

• Shareholders: May react to the news of an institutional investor exiting, potentially leading to short-term price volatility if interpreted negatively.
• Y-mAbs Therapeutics: The company loses an institutional shareholder, which could slightly reduce institutional support or liquidity, though the overall impact is likely minimal given the passive nature of the investment.

Key Dates

Recommendation

This Schedule 13G Amendment No. 2 merely reports the complete divestment of Y-mAbs Therapeutics, Inc. common stock by Paradigm BioCapital Advisors and its affiliates. While the exit of an institutional investor can sometimes signal concerns, this filing provides no specific reasons for the divestment or any new information regarding Y-mAbs's operational or financial performance. Therefore, a 'hold' recommendation is appropriate as investors should rely on fundamental analysis of Y-mAbs's business, pipeline, and financial health rather than solely on this ownership change.

Keywords

Y-mAbs Therapeutics, Paradigm BioCapital, Schedule 13G, Divestment, Common Stock, Institutional Ownership, SEC Filing, Biotechnology, Pharmaceutical